Zydus' sales up by 21% on formulations, US growth
This article was originally published in Scrip
Zydus Cadila has reported a 21% increase in net sales to Rs11.06 billion ($249.4 million) for the second quarter ended 30 September compared with the same quarter in the previous year, backed by strong growth in its formulations and US businesses. Net profit rose by 30% to Rs1.70 billion.
You may also be interested in...
Scrip traces some of the prominent changes in the corner office at front-line, family-owned Indian firms Cipla and Dr Reddy’s in the decade gone by.
Glenmark has struck a deal with private equity firm True North for its gynecology business in India and Nepal.
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.